Browse

You are looking at 31 - 40 of 2,237 items for

  • Refine by access: Content accessible to me x
Clear All
Nidhi Singh Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA

Search for other papers by Nidhi Singh in
Google Scholar
PubMed
Close
and
Hannelore V Heemers Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA

Search for other papers by Hannelore V Heemers in
Google Scholar
PubMed
Close

Prostate cancer (CaP) remains the second leading cause of cancer-related mortality in American men. Systemic treatments for metastatic CaP, which causes the majority of deaths, include androgen deprivation therapy and chemotherapy. These treatments induce remissions but do not cure CaP. Novel and functionally diverse therapeutic targets that control the cell biology that drives aggressive CaP progression are needed to overcome treatment resistance. Because signal transduction that mediates CaP cell behavior is tightly regulated by phosphorylation, kinases have attracted interest as alternative targets for CaP treatments. Here, we examine emerging evidence from recent NextGen sequencing and (phospho) proteomics analyses on clinical CaP specimens that were obtained during lethal disease progression to determine the role of deregulated kinase action in CaP growth, treatment resistance, and recurrence. We provide an overview of kinases that are impacted by gene amplification, gene deletion or somatic mutations during the progression from localized treatment-naïve CaP to metastatic castration-resistant CaP or neuroendocrine CaP, and the potential impact of such alterations on aggressive CaP behavior and treatment efficacy. Furthermore, we review knowledge on alterations in the phosphoproteome that occur during the progression to treatment-resistant CaP, the molecular mechanisms in the control of these changes, and the signal transduction associated with them. Finally, we discuss kinase inhibitors under evaluation in CaP clinical trials and the potential, challenges, and limitations to moving knowledge on the CaP kinome forward to new therapeutic strategies.

Free access
Krystallenia I Alexandraki Department of Surgery, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Krystallenia I Alexandraki in
Google Scholar
PubMed
Close
,
Gregory A Kaltsas Department of Propaedeutic Internal Medicine, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Search for other papers by Gregory A Kaltsas in
Google Scholar
PubMed
Close
, and
Simona Grozinsky-Glasberg Department of Endocrinology and Metabolism, Neuroendocrine Tumor Unit, ENETS Center of Excellence, Hadassah Medical Organization and Faculty of Medicine, the Hebrew University, Jerusalem, Israel

Search for other papers by Simona Grozinsky-Glasberg in
Google Scholar
PubMed
Close

Pancreatic neuroendocrine neoplasms (panNENs) are rare relatively malignancies that, despite their frequently slow-growing pattern, have the ability to metastasize. Metastatic and/or advanced insulinomas and glucagonomas are functioning panNENs emerging from the pancreas displaying unique peculiarities, depending on their hormonal syndromes and increased malignant potential. Advanced insulinomas management follows usually the panNENs therapeutic algorithm, but some distinctions are well advised together with aiming to control hypoglycemias that occasionally can be severe and refractory to treatment. When first-generation somatostatin analogues (SSAs) fail to control hypoglycemia syndrome, second-generation SSAs and everolimus have to be considered for exploiting their hyperglycemic effect. There is evidence that everolimus is still effective after rechallenge retaining its hypoglycemic effect independently of its antitumor effect that seems to be mediated by different molecular pathways. Peptide receptor radionuclide therapy (PRRT) constitutes a promising therapeutic option for both its antisecretory and antitumoral action. Similarly, advanced and/or metastatic glucagonomas management also follows the panNENs therapeutic algorithm, but the clinical syndrome has to be addressed by aminoacid infusion and by first-generation SSAs to improve the patient performance status. PRRT seems to be an effective treatment when surgery and SSAs fail. The application of these therapeutic modalities has been shown to be efficacious in controlling the manifestations of the secretory syndrome and prolonging the overall survival of patients suffering from these malignancies.

Free access
Reetobrata Basu Edison Biotechnology Institute, Athens, Ohio, USA

Search for other papers by Reetobrata Basu in
Google Scholar
PubMed
Close
and
John J Kopchick Edison Biotechnology Institute, Athens, Ohio, USA
Molecular and Cellular Biology Program, Ohio University, Athens, Ohio, USA
Heritage College of Osteopathic Medicine, Ohio University, Athens, Ohio, USA

Search for other papers by John J Kopchick in
Google Scholar
PubMed
Close

Despite landmark advances in cancer treatments over the last 20 years, cancer remains the second highest cause of death worldwide, much ascribed to intrinsic and acquired resistance to the available therapeutic options. In this review, we address this impending issue, by focusing the spotlight on the rapidly emerging role of growth hormone action mediated by two intimately related tumoral growth factors – growth hormone (GH) and insulin-like growth factor 1 (IGF1). Here, we not only catalog the scientific evidences relating specifically to cancer therapy resistance inflicted by GH and IGF1 but also discuss the pitfalls, merits, outstanding questions and the future need of exploiting GH–IGF1 inhibition to tackle cancer treatment successfully.

Free access
Erin Gibbons Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Rochester Medical Center, Rochester, New York, USA
Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA

Search for other papers by Erin Gibbons in
Google Scholar
PubMed
Close
,
Briaunna M N Minor Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Rochester Medical Center, Rochester, New York, USA
Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, New York, USA

Search for other papers by Briaunna M N Minor in
Google Scholar
PubMed
Close
, and
Stephen R Hammes Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, University of Rochester Medical Center, Rochester, New York, USA

Search for other papers by Stephen R Hammes in
Google Scholar
PubMed
Close

Graphical abstract

Abstract

Lymphangioleiomyomatosis (LAM) is a cystic lung disease found almost exclusively in genetic females and caused by small clusters of smooth muscle cell tumors containing mutations in one of the two tuberous sclerosis genes (TSC1 or TSC2). Significant advances over the past 2–3 decades have allowed researchers and clinicians to more clearly understand the pathophysiology of LAM, and therefore better diagnose and treat patients with this disease. Despite substantial progress, only one proven treatment for LAM is used in practice: mechanistic target of rapamycin complex 1 (mTORC1) inhibition with medications such as sirolimus. While mTORC1 inhibition effectively slows LAM progression in many patients, it is not curative, is not effective in all patients, and can be associated with significant side effects. Furthermore, the presence of established and accurate biomarkers to follow LAM progression is limited. That said, discovering additional diagnostic and treatment options for LAM is paramount. This review will describe recent advances in LAM research, centering on the origin and nature of the LAM cell, the role of estrogen in LAM progression, the significance of melanocytic marker expression in LAM cells, and the potential roles of the microenvironment in promoting LAM tumor growth. By appreciating these processes in more detail, researchers and caregivers may be afforded novel approaches to aid in the treatment of patients with LAM.

Free access
Wouter W de Herder Department of Internal Medicine, Sector of Endocrinology, Erasmus MC & Erasmus MC Cancer Institute, ENETS Center of Excellence, Rotterdam, the Netherlands

Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
Close
and
Günter Klöppel Department of Pathology, Technical University Munich, Munich, Germany

Search for other papers by Günter Klöppel in
Google Scholar
PubMed
Close

One century ago, in 1922, Frederick G Banting, Charles H Best, James B Collip and John J R Macleod first published their experiments resulting in the isolation of a hypoglycemic factor, named insulin, from a solution extract from a dog’s pancreas. One year later, in 1923, a hyperglycemic factor named glucagon was isolated by Charles P Kimball and John R Murlin. In the following years, it could be demonstrated that pancreatic islet alpha- and beta-cell neoplasms and hyperplasias could inappropriately secrete excessive amounts of these two hormones. This review is a sequel to the discovery of insulin and glucagon and introduces the history of this fascinating group of neuroendocrine neoplasms and hyperplasias of the pancreas.

Free access
Christine Sempoux Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland

Search for other papers by Christine Sempoux in
Google Scholar
PubMed
Close
and
Günter Klöppel Department of Pathology, Technical University Munich, Munich, Germany

Search for other papers by Günter Klöppel in
Google Scholar
PubMed
Close

Nesidioblastoma and nesidioblastosis were terms given to neoplastic and non-neoplastic lesions of the pancreas associated with pancreatogenous hyperinsulinaemic hypoglycaemia. While nesidioblastoma was rapidly replaced by islet cell tumour, nesidioblastosis, defined as the proliferation of islet cells budding off from pancreatic ducts, was the diagnostic term associated with congenital hyperinsulinism of infancy (CHI) and adult non-neoplastic hyperinsulinaemic hypoglycaemia (ANHH). When it was shown that nesidioblastosis was not specific for CHI or ANHH, it was no longer applied to CHI but kept for the morphological diagnosis of ANHH. In severe CHI cases, a diffuse form with hypertrophic ß-cells in all islets can be distinguished from a focal form with hyperactive ß-cells changes in a limited adenomatoid hyperplastic area. Genetically, mutations were identified in several ß-cell genes involved in insulin secretion. Most common are mutations in the ABCC8 or KCNJ11 genes, solely affected in the diffuse form and associated with a focal maternal allelic loss on 11p15.5 in the focal form. Focal CHI can be localized by 18F-DOPA-PET and is thus curable by targeted resection. Diffuse CHI that fails medical treatment requires subtotal pancreatectomy. In ANHH, an idiopathic form can be distinguished from a form associated with gastric bypass, in whom GLP1-induced stimulation of the ß-cells is discussed. While the ß-cells in idiopathic ANHH are diffusely affected and are either hypertrophic or show only little changes, it is controversial whether there is a ß-cell increase or ß-cell hyperactivity in patients with gastric bypass. Recognizing morphological signs of ß-cell hyperactivity needs a good knowledge of the non-neoplastic endocrine pancreas across all ages.

Free access
Kristina V Wells Department of Anatomy, Physiology, and Cell Biology, University of California Davis School of Veterinary Medicine, Davis, California, USA

Search for other papers by Kristina V Wells in
Google Scholar
PubMed
Close
,
Margaret L Krackeler Department of Internal Medicine, University of California Davis School of Medicine, Sacramento, California, USA

Search for other papers by Margaret L Krackeler in
Google Scholar
PubMed
Close
,
Maitreyee K Jathal Department of Medical Microbiology and Immunology, University of California Davis, Davis, California, USA
Veterans Affairs-Northern California Health System, Mather, California, USA

Search for other papers by Maitreyee K Jathal in
Google Scholar
PubMed
Close
,
Mamta Parikh Division of Hematology and Oncology, School of Medicine, University of California Davis, Sacramento, California, USA

Search for other papers by Mamta Parikh in
Google Scholar
PubMed
Close
,
Paramita M Ghosh Veterans Affairs-Northern California Health System, Mather, California, USA
Department of Urologic Surgery, School of Medicine, University of California Davis, Sacramento, California, USA

Search for other papers by Paramita M Ghosh in
Google Scholar
PubMed
Close
,
J Kent Leach Department of Orthopaedic Surgery, School of Medicine, University of California Davis, Sacramento, California, USA
Department of Biomedical Engineering, University of California Davis, Davis, California, USA

Search for other papers by J Kent Leach in
Google Scholar
PubMed
Close
, and
Damian C Genetos Department of Anatomy, Physiology, and Cell Biology, University of California Davis School of Veterinary Medicine, Davis, California, USA

Search for other papers by Damian C Genetos in
Google Scholar
PubMed
Close

Prostate cancer (PCa) is an increasingly prevalent health problem in the developed world. Effective treatment options exist for localized PCa, but metastatic PCa has fewer treatment options and shorter patient survival. PCa and bone health are strongly entwined, as PCa commonly metastasizes to the skeleton. Since androgen receptor signaling drives PCa growth, androgen-deprivation therapy whose sequelae reduce bone strength constitutes the foundation of advanced PCa treatment. The homeostatic process of bone remodeling – produced by concerted actions of bone-building osteoblasts, bone-resorbing osteoclasts, and regulatory osteocytes — may also be subverted by PCa to promote metastatic growth. Mechanisms driving skeletal development and homeostasis, such as regional hypoxia or matrix-embedded growth factors, may be subjugated by bone metastatic PCa. In this way, the biology that sustains bone is integrated into adaptive mechanisms for the growth and survival of PCa in bone. Skeletally metastatic PCa is difficult to investigate due to the entwined nature of bone biology and cancer biology. Herein, we survey PCa from origin, presentation, and clinical treatment to bone composition and structure and molecular mediators of PCa metastasis to bone. Our intent is to quickly yet effectively reduce barriers to team science across multiple disciplines that focuses on PCa and metastatic bone disease. We also introduce concepts of tissue engineering as a novel perspective to model, capture, and study complex cancer-microenvironment interactions.

Free access
Yue Wang Liggins Institute, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand

Search for other papers by Yue Wang in
Google Scholar
PubMed
Close
,
Stephen M F Jamieson Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand
Auckland Cancer Society Research Centre, University of Auckland, Auckland, New Zealand
Department of Pharmacology and Clinical Pharmacology, University of Auckland, Auckland, New Zealand

Search for other papers by Stephen M F Jamieson in
Google Scholar
PubMed
Close
, and
Jo K Perry Liggins Institute, University of Auckland, Auckland, New Zealand
Maurice Wilkins Centre for Molecular Biodiscovery, Auckland, New Zealand

Search for other papers by Jo K Perry in
Google Scholar
PubMed
Close

Decades of published research support a role for growth hormone (GH) in cancer. Accordingly, there is increasing interest in targeting GH in oncology, with GH antagonists exhibiting efficacy in xenograft studies as single agents and in combination with anticancer therapy or radiation. Here we discuss challenges associated with using growth hormone receptor (GHR) antagonists in preclinical models and considerations for translation, such as the identification of predictive biomarkers for selecting patients and for monitoring drug efficacy. Ongoing research will determine whether suppressing GH signalling pharmacologically will also reduce the risk of developing cancer. An increase in GH-targeted drugs in preclinical development will ultimately provide new tools to test anticancer efficacy of blocking the GH signalling pathway.

Free access
Yuanliang Li Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing University of Chinese Medicine, Beijing, China

Search for other papers by Yuanliang Li in
Google Scholar
PubMed
Close
,
Yiying Guo Department of Integrative Oncology, China-Japan Friendship Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China

Search for other papers by Yiying Guo in
Google Scholar
PubMed
Close
,
Zixuan Cheng Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing University of Chinese Medicine, Beijing, China

Search for other papers by Zixuan Cheng in
Google Scholar
PubMed
Close
,
Chao Tian Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing University of Chinese Medicine, Beijing, China

Search for other papers by Chao Tian in
Google Scholar
PubMed
Close
,
Yingying Chen Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing University of Chinese Medicine, Beijing, China

Search for other papers by Yingying Chen in
Google Scholar
PubMed
Close
,
Ruao Chen Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing University of Chinese Medicine, Beijing, China

Search for other papers by Ruao Chen in
Google Scholar
PubMed
Close
,
Fuhuan Yu Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing University of Chinese Medicine, Beijing, China

Search for other papers by Fuhuan Yu in
Google Scholar
PubMed
Close
,
Yanfen Shi Department of Pathology, China-Japan Friendship Hospital, Beijing, China

Search for other papers by Yanfen Shi in
Google Scholar
PubMed
Close
,
Fei Su Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, China

Search for other papers by Fei Su in
Google Scholar
PubMed
Close
,
Shuhua Zhao Department of Biological Information Research, HaploX Biotechnology Co., Ltd, Shenzhen, Guangdong, China

Search for other papers by Shuhua Zhao in
Google Scholar
PubMed
Close
,
Zhizheng Wang Academic Department, HaploX Biotechnology, Co., Ltd, Shenzhen, Guangdong, China

Search for other papers by Zhizheng Wang in
Google Scholar
PubMed
Close
,
Jie Luo Department of Pathology, China-Japan Friendship Hospital, Beijing, China

Search for other papers by Jie Luo in
Google Scholar
PubMed
Close
, and
Huangying Tan Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing University of Chinese Medicine, Beijing, China
Department of Integrative Oncology, China-Japan Friendship Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China
Department of Integrative Oncology, China-Japan Friendship Hospital, Beijing, China

Search for other papers by Huangying Tan in
Google Scholar
PubMed
Close

The genetic characteristics of rectal neuroendocrine tumors (R-NETs) were poorly understood. Depicting the genetic characteristics may provide a biological basis for prognosis prediction and novel treatment development. Tissues of 18 R-NET patients were analyzed using whole-exome sequencing. The median tumor mutation burden (TMB) and microsatellite instability (MSI) were 1.15 Muts/MB (range, 0.03–23.28) and 0.36 (range, 0.00–10.97), respectively. Genes involved in P53 signaling, PI3K-AKT signaling, DNA damage repair, WNT signaling, etc. were frequently altered. Higher TMB (P = 0.078), higher CNV (P = 0.110), somatic mutation of CCDC168 (P = 0.049), HMCN1 (P = 0.040), MYO10 (P = 0.007), and amplification of ZC3H13 (P < 0.001) were associated with shorter OS. Potentially targetable gene alterations (PTGAs) were seen in 72% of the patients. FGFR1 amplification (22%) was the most common PTGA followed by BARD1 and BRCA2 mutation (each 17%). As for gene variations associated with the efficacy of immune checkpoint blockade (ICB), FAT1 alteration (39%) and PTEN depletion (28%) were commonly observed. In conclusion, frequently altered oncogenic pathways might contribute to the development and progression of R-NETs. Gene alterations significantly associated with prognosis might be potential novel targets. Targeted therapy might be a promising strategy as targetable alterations were prevalent in R-NETs. FAT1 alteration and PTEN depletion might be the main genetic alterations influencing the response to ICB besides overall low TMB and MSI in R-NETs.

Open access
Meilin Zhang Department of Burn and Plastic Surgery, Chaoyang Central Hospital, Chaoyang, Liaoning Province, China

Search for other papers by Meilin Zhang in
Google Scholar
PubMed
Close
,
Jian Song Department of Breast Surgery, the First Hospital of China Medical University, Shenyang, Liaoning Province, China

Search for other papers by Jian Song in
Google Scholar
PubMed
Close
,
Shigang Guo Department of General Surgery, Chaoyang Central Hospital, Chaoyang, Liaoning Province, China

Search for other papers by Shigang Guo in
Google Scholar
PubMed
Close
,
Feng Jin Department of Breast Surgery, the First Hospital of China Medical University, Shenyang, Liaoning Province, China

Search for other papers by Feng Jin in
Google Scholar
PubMed
Close
, and
Ang Zheng Department of Breast Surgery, the First Hospital of China Medical University, Shenyang, Liaoning Province, China

Search for other papers by Ang Zheng in
Google Scholar
PubMed
Close

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have shown advantages in hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) advanced breast cancer. This study aimed to evaluate the efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy (ET) in patients with HR+, HER2− early breast cancer. The PubMed, Embase, Cochrane Library, and Web of Science databases were searched for randomized controlled trials (RCTs) related to CDK4/6 inhibitors combined with ET. Literature conforming to the research content was identified according to the inclusion and exclusion criteria. The efficacy endpoints included invasive disease-free survival (IDFS), distant relapse-free survival (DRFS), and overall survival (OS) with adjuvant therapy. The efficacy endpoint of neoadjuvant therapy was complete cell cycle arrest (CCCA). The safety outcomes included the incidence of adverse events (AEs) and grade 3–4 hematological and non-hematological AEs. Data analysis was performed using Review Manager software (version 5.3). A statistical model (fixed-effects model or random-effects model) was selected based on the level of heterogeneity, and a sensitivity analysis was performed if strong heterogeneity existed. Subgroup analyses were performed based on the baseline patient characteristics. Nine articles (including six RCTs) were included in the study. In adjuvant therapy, compared with the control group, CDK4/6 inhibitors combined with ET showed no statistically significant difference in IDFS (hazard ratio = 0.83, 95% confidence interval (CI) = 0.64–1.08, P = 0.17) and DRFS (hazard ratio = 0.83, 95% CI = 0.52–1.31, P = 0.42). In neoadjuvant therapy, CDK4/6 inhibitors combined with ET significantly improved CCCA compared with the control group (odds ratio = 9.00, 95% CI = 5.42–14.96, P < 0.00001). In terms of safety, the combination treatment group had a significantly increased incidence of grade 3–4 hematological AEs in patients, especially grade 3–4 neutropenia (risk ratio (RR) = 63.90, 95% CI = 15.44–264.41, P < 0.00001) and grade 3–4 leukopenia (RR = 85.89, 95% CI = 19.12–385.77, P < 0.00001), with statistically significant differences. In patients with HR+, HER2− early breast cancer, the addition of CDK4/6 inhibitors may prolong IDFS and DRFS in adjuvant therapy, especially in high-risk patients. Further follow-up is needed to establish whether OS can be improved with CDK4/6 inhibitors plus ET. CDK4/6 inhibitors also showed effective anti-tumor proliferation activity in neoadjuvant therapy. Regular monitoring of routine blood tests in patients using CDK4/6 inhibitors is essential.

Free access